AO
VRTX icon

Advisor OS’s Vertex Pharmaceuticals VRTX Stock Holding History

Advisor OS’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-543
Closed -$263K – 487
2025
Q1 		$263K Buy
543
+23
+4% +$10.7K 0.03% 353
2024
Q4 		$209K Sell
520
-18
-3% -$8.34K 0.02% 394
2024
Q3 		$250K Sell
538
-7
-1% -$3.36K 0.02% 348
2024
Q2 		$255K Buy
545
+51
+10% +$22.1K 0.03% 333
2024
Q1 		$206K Buy
+494
New +$209K 0.02% 373

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Advisor OS's VRTX Position: Q2 2025 in Review

Advisor OS sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 543 shares — an estimated $263K sold.

Advisor OS first reported a position in VRTX in Q1 2024 and held it in 5 quarters. The position peaked at $263K in Q1 2025. 1,559 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

  • Advisor OS reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Advisor OS sold 543 Vertex Pharmaceuticals shares in Q2 2025, an estimated $263K.
  • Advisor OS first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Advisor OS's Vertex Pharmaceuticals position peaked at $263K in Q1 2025.
  • 1,559 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Advisor OS's 13F filing for Q2 2025, filed 14 Aug 2025.